First-line nivolumab (NIVO) plus ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Reck, M.
Ciuleanu, T-E.
Cobo, M.
Schenker, M.
Zurawski, B.
Menezes, J.
Richardet, E.
Bennouna, J.
Cheng, Y.
Paz-Ares, L.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
